SAFETY SIGNAL DETECTION OF CARDIAC DISORDERS ADVERSE DRUG EVENTS FOR AZITHROMYCIN IN PEDIATRIC POPULATION USING HEALTH CANADA ADVERSE EVENT REPORTING SYSTEM DATABASE
DOI:
https://doi.org/10.22159/ijpps.2017v9i6.18020Keywords:
Signal detection, Drug Safety, Pediatrics, Medeffect, Pharmacovigilance, AzithromycinAbstract
Objective: We conducted signal detection of adverse drug events reported in Health Canada adverse event reporting system database MedEffect†for azithromycin, a macrolide derivative and the first azalide antimicrobial agent to review the cardiac disorders adverse drug events (ADEs) in pediatric population with the drug labels of selected countries including India, USA, UK, Canada, Switzerland, Australia, New Zealand.
Methods: We extracted data between January 1965 and June 2016 from the Canada adverse event reporting system database MedEffectâ€. Frequentist and Bayesian methods were used to calculate disproportionality distribution of drug-adverse event (AE) pairs. The AE which was detected by all the three indices of proportional reporting ratio (PRR), reporting odds ratio (ROR), and information component (IC) was identified as a potential signal. AE reports for azithromycin, among which 3651 reports were attributed to paediatrics.
Results: The signal detected by PRR and ROR for tachycardia associated with azithromycin were found to be 1.3 and for cardiovascular disorder were 1.2. The IC for azithromycin by a Bayesian method was 0.3 for both, tachycardia and cardiovascular disorder. Both AEs of cardiovascular disorder and tachycardia were detected as potential signals of azithromycin for the paediatric population. Comparing drug labels of 7 countries in paediatric population, both adverse events were not listed on any of the labels of seven countries against the pediatric population.
Conclusion: We detected 2 new potential signals of azithromycin which were not listed on the labels of 7 countries. Therefore, it should be accompanied by a signal evaluation including causal association, clinical significance, and preventability.
Downloads
References
Williams JD. Spectrum of activity of azithromycin. Eur J Clin Microbiol Infect Dis 1991;10:813-20.
AZITHROMYCIN label. Available from: http://www.accessdata. fda.gov/spl/data/2e0577d5-adb9-6c8d-e054-00144ff8d46c/2e0577d5-adb9-6c8d-e054-00144ff8d46c.xml. [Last accessed on 18 Feb 2017].
Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013;108:18-37.
Zuckerman JM, Qamar F, Bono BR. Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North A 2009;23:997-1026, ix-x.
Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J 2003; 116:U666.
Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycinâ€induced torsade de points. Pacing Clin Electrophysiol 2007;30:1579-82.
FDA Drug Safety Communication [AZITHROMYCIN]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm341822.htm. [Last accessed on 18 Feb 2017].
Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
Balaji V, Sivaraj R, Nirmala P. Comparative study of safety and efficacy of azithromycin and amoxicillin in treating children with lower respiratory tract infection. Int J Curr Pharm Res 2015;7:56-7.
WHO Guideline: Setting Up and Running a Pharmacovigilance Centre. Available from: http://apps.who.int/medicinedocs/ en/d/Jh2934e/14.html. [Last accessed on 18 Feb 2017]
Ramesh M, Parthasarathi G. Adverse drug reactions reporting: attitudes and perceptions of medical practitioners. Asian J Pharm Clin Res 2009;2:10-4.
Harpaz R, DuMouchel W, LePendu P, Bauerâ€Mehren A, Ryan P, Shah NH. The performance of pharmacovigilance signalâ€detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 2013;93:539-46.
Sakaeda T, Kadoyama K, Okuno Y. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci 2011;8:487-91.
MedEffect Canada. Available from: http://www.hc-sc.gc.ca/ dhp-mps/medeff/databasdon/index-eng.php. [Last accessed on 18 Feb 2017]
Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001;10:483-6.
Kajungu D, Speybroeck N. Implementation of signal detection methods in pharmacovigilance–a case for their application to safety data from developing countries. Ann Biom Biostat 2015;2:1017.
Dykens JA, Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discovery Today 2007;12:777-85.
Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J 2014;22:83-94.
Priyadharsini R, Surendiran A, Adithan C, Sreenivasan S, Sahoo FK. A study of adverse drug reactions in pediatric patients. J Pharmacol Pharmacother 2011;2:277-80.
Alvarez Y, Hidalgo A, Maignen F, Slattery J. Validation of statistical signal detection procedures in Eudra vigilance post-authorization data. Drug Saf 2010;33:475-87.
Hochberg AM, Reisinger SJ, Pearson RK, O'Hara DJ, Hall K. Using data mining to predict safety actions from FDA adverse event reporting system data. Drug Inf J 2007;41:633-43.
Almenoff JS, LaCroix KK, Yuen NA, Fram D, DuMouchel W. Comparative performance of two quantitative safety signalling methods. Drug Saf 2006;29:875-87.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
Published
How to Cite
Issue
Section
